Population-based outcomes in large b-cell lymphona by WHO subtype: findings from the UK's haematological malignancy research network

R. Patmore; A. Smith; S. Barrans; D. Painter; D. Howell; C. Burton; E. Roman

doi:10.1002/hon.10_2630

Population-based outcomes in large b-cell lymphona by WHO subtype: findings from the UK's haematological malignancy research network

R. Patmore, A. Smith, S. Barrans, D. Painter, D. Howell, C. Burton, E. Roman

Health Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Introduction: Distinct morphologic, molecular and immunophenotypic variants of large B-cell lymphoma are well recognised, but information on their outcomes in the general (non-trial) patient populations is scarce. With centralised diagnostics at HMDS, Leeds and a unified clinical network covering a catchment population of ~4 million, the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) was established to provide timely real-world data to answer such questions; and the findings are reported here.

Original language	English
Pages (from-to)	196-197
Number of pages	2
Journal	Hematological Oncology
Volume	37
Issue number	S2
DOIs	https://doi.org/10.1002/hon.10_2630
Publication status	Published - 12 Jun 2019
Event	15th International Conference on Malignant Lymphoma - Palazzo dei COngressi, Lugano, Switzerland Duration: 18 Jun 2019 → 22 Jun 2019

Access to Document

10.1002/hon.10_2630

Cite this

@article{59f206fedb37412e8a17d7a82ab5cc4d,

title = "Population-based outcomes in large b-cell lymphona by WHO subtype: findings from the UK's haematological malignancy research network",

abstract = "Introduction: Distinct morphologic, molecular and immunophenotypic variants of large B-cell lymphoma are well recognised, but information on their outcomes in the general (non-trial) patient populations is scarce. With centralised diagnostics at HMDS, Leeds and a unified clinical network covering a catchment population of ~4 million, the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) was established to provide timely real-world data to answer such questions; and the findings are reported here.",

author = "R. Patmore and A. Smith and S. Barrans and D. Painter and D. Howell and C. Burton and E. Roman",

year = "2019",

month = jun,

day = "12",

doi = "10.1002/hon.10_2630",

language = "English",

volume = "37",

pages = "196--197",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "Wiley-Blackwell",

number = "S2",

note = "15th International Conference on Malignant Lymphoma ; Conference date: 18-06-2019 Through 22-06-2019",

}

TY - JOUR

T1 - Population-based outcomes in large b-cell lymphona by WHO subtype

T2 - 15th International Conference on Malignant Lymphoma

AU - Patmore, R.

AU - Smith, A.

AU - Barrans, S.

AU - Painter, D.

AU - Howell, D.

AU - Burton, C.

AU - Roman, E.

PY - 2019/6/12

Y1 - 2019/6/12

N2 - Introduction: Distinct morphologic, molecular and immunophenotypic variants of large B-cell lymphoma are well recognised, but information on their outcomes in the general (non-trial) patient populations is scarce. With centralised diagnostics at HMDS, Leeds and a unified clinical network covering a catchment population of ~4 million, the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) was established to provide timely real-world data to answer such questions; and the findings are reported here.

AB - Introduction: Distinct morphologic, molecular and immunophenotypic variants of large B-cell lymphoma are well recognised, but information on their outcomes in the general (non-trial) patient populations is scarce. With centralised diagnostics at HMDS, Leeds and a unified clinical network covering a catchment population of ~4 million, the UK's population-based Haematological Malignancy Research Network (www.hmrn.org) was established to provide timely real-world data to answer such questions; and the findings are reported here.

U2 - 10.1002/hon.10_2630

DO - 10.1002/hon.10_2630

M3 - Meeting abstract

SN - 0278-0232

VL - 37

SP - 196

EP - 197

JO - Hematological Oncology

JF - Hematological Oncology

IS - S2

Y2 - 18 June 2019 through 22 June 2019

ER -